Efficacy and safety profile of Sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects

2021 ◽  
Author(s):  
Sahar Hossam Elhini ◽  
Amal Kmal Hussien ◽  
Ahmed Abd Elsamie Omran ◽  
Asmaa A. Elsayed ◽  
Haitham saeed
Keyword(s):  
Safety Profile ◽  
Newly Diagnosed ◽  
Efficacy And Safety ◽  
Type 2 Diabetic

scholarly journals To compare the efficacy and safety profile of sitagliptin and glimipiride in type 2 diabetic patients.

2020 ◽  
Vol 27 (05) ◽  
pp. 895-901
Author(s):  
Mazhar Hussain ◽  
Muhammad Amir Rafique ◽  
Abdul Qudoos Arain ◽  
Shoaib Akhtar ◽  
Muhammad Bilal Ghafoor ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Adverse Effects ◽  
Safety Profile ◽  
Treated Group ◽  
Pronounced Effect ◽  
Diabetic Patients ◽  
Efficacy And Safety ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Objectives: To compare the efficacy and safety profile of sitagliptin vs. glimepiride in type 2 diabetic patients. Study Design: Comparative study. Setting: At Islam Central Hospital, Sialkot at its Medical outdoor unit. Period: 16 week from September to December 2018. Materials & Methods: In which Type 2 diabetic patients (n=220) were randomly placed into interventional groups to prescribed either sitagliptin or glimepiride for an interval of 16 weeks. A blood sugar level was maintained by dose titration in both groups. The main end point was change in FBG & HbA1C while additional end point was change in body weight, hypoglycemic episodes and gastrointestinal adverse effects from baseline by using SPPS 16. Results: After 16 weeks of treatment both sitagliptin and glimepiride caused a significant improvement (P<0.001) in glycemic control by reducing FBG (-22±3.2 &-33.5±4.4) & HbA1c (0.78±0.3 & 1.12±0.25) respectively. However when comparison was done between two group, glimepiride has more pronounced effect on glycemic control as compared to sitagliptin (P<0.001). Net BMI reduced to 0.8±0.68 in sitagliptin group while net BMI increased to 1.1±0.78 in glimepiride treated group with (P<0.001). There were no adverse effects reported in sitagliptin treated group while 25 hypoglycemic episodes were noticed in glimepiride treated group. Conclusion: Glimepiride has more pronounced effect on glycemic control as compared to sitagliptin. However this pronounced effect was associated with more hypoglycemic episodes and weight gain. Euglycemic effect and weight reducing property of sitagliptin precludes that it has better safety and tolerability profile in comparison with glimepiride.

scholarly journals Evaluating the Synergistic Activity of Metformin and Apple Cider Vinegar in Type 2 Diabetics

2020 ◽  
pp. 1-7
Author(s):  
Momina Abid ◽  
Farah Ahmed ◽  
Shehla Shaheen ◽  
Zahida Memon ◽  
M. Zaman Shaikh ◽  
...  
Keyword(s):  
Glycemic Control ◽  
The Body ◽  
Diabetic Patients ◽  
Synergistic Activity ◽  
Care Hospital ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Apple Cider ◽  
Type 2 Diabetic

Aims: The aim of this study was to observe the effect of Apple Cider Vinegar (ACV) in combination with Metformin on the Body Mass Index (BMI) and glycemic control of newly diagnosed type 2 diabetic patients. Study Design: Single arm pre post quasi experimental clinical trial. Place and Duration of Study: Department of Medicine of a tertiary care hospital and a Diabetes and Endocrinology clinic, based in Karachi, Pakistan from April to July 2019. Methodology: A total of 30 newly diagnosed type 2 diabetic patients were enrolled in the study (Males: 17; females: 13; age range: 27-55 years) after obtaining written informed consent. The parameters of Body weight, BMI, Fasting Blood Sugar (FBS) and Hemoglobin A1c (HbA1c) of each patient were assessed before and after 12 weeks of treatment with Metformin 750 mg plus 2 tablespoons of ACV per day. The baseline and post treatment values of the aforementioned were compared with each other. Results: In all the 30 patients assessed after 12 weeks of treatment, the weight was significantly reduced from 85.66±18.30 kg. to 82.96±18.43 kg with a consequently significant change in the BMI from 29.38±5.08 kg/m2 to 28.43±5.16 kg/m2. Moreover, the glycemic control, assessed as FBS and HbA1c also showed significant reduction in the FBS (127.76±9.17 to 121.23±9.54) and HbA1c (7.14±0.29 to 6.92±0.29) after 12 weeks of treatment in all 30 patients (p<0.01). Conclusion: Apple Cider Vinegar seems to be effective therapy in combination with metformin for newly diagnosed type 2 diabetic patients in improving glycemic control as well as augmenting weight reduction.

Sign in / Sign up

Export Citation Format

Share Document